TY - JOUR
T1 - Randomised clinical trial
T2 - Psychological intervention improves work productivity and daily activity by reducing abdominal pain and fatigue in Crohn's disease
AU - Regev, Shirley
AU - Schwartz, Doron
AU - Sarid, Orly
AU - Goren, Ganit
AU - Slonim-Nevo, Vered
AU - Friger, Michael
AU - Sergienko, Ruslan
AU - Greenberg, Dan
AU - Monsonego, Alon
AU - Nemirovsky, Anna
AU - Odes, Shmuel
N1 - Publisher Copyright:
© 2023 John Wiley & Sons Ltd.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - Background: Chronic abdominal pain and fatigue are characteristics of Crohn's disease (CD) and contribute to functional impairments. Aims: To examine whether CD-tailored cognitive-behavioural and mindfulness intervention (COBMINDEX) is effective in reducing abdominal pain and fatigue in patients with CD and whether changes in abdominal pain and fatigue mediate any beneficial effects of COBMINDEX on impairments in work productivity and daily activities. Methods: This is a secondary analysis of a parallel-group multicentre randomised controlled trial. Patients with mild-to-moderate CD (n = 142) were randomised into either intervention group receiving COBMINDEX, or control group receiving treatment-as-usual for 3 months followed by COBMINDEX. Complete data were collected from 120 patients (34.0 ± 10.7 years, 62.5% female, intervention = 60, control = 60). Analysis of covariance assessed group differences in 3-month follow-up scores, controlling for baseline scores. Multiple parallel mediation analysis assessed the proposed mechanisms for the entire sample. Results: The intervention group demonstrated significantly lower levels of abdominal pain (F = 17.46, p < 0.001, η2p = 0.13), fatigue (F = 7.26, p = 0.008, η2p = 0.06) and impairments at work (F = 4.82, p = 0.032, η2p = 0.07) and daily activities (F = 6.26, p = 0.014, η2p = 0.05), compared with treatment-as-usual. Moreover, changes in abdominal pain and fatigue significantly mediated the beneficial effects of COBMINDEX on patients' work productivity (b = −9.90, SE = 2.86, 95% CI: −16.11 to −4.94) and daily activities (b = −9.65, SE = 1.91, 95% CI: −13.77 to 6.35), independent of changes in disease activity. Conclusions: COBMINDEX is effective at reducing abdominal pain and fatigue in patients with CD, which in turn leads to improvement in functioning. Clinicians should incorporate screening for severe abdominal pain and fatigue and consider offering cognitive-behavioural and mindfulness training. ClinicalTrials.gov, Number: NCT05085925. Ministry of Health in Israel (https://my.health.gov.il/CliniTrials/Pages/MOH_2020-02-24_008721.aspx).
AB - Background: Chronic abdominal pain and fatigue are characteristics of Crohn's disease (CD) and contribute to functional impairments. Aims: To examine whether CD-tailored cognitive-behavioural and mindfulness intervention (COBMINDEX) is effective in reducing abdominal pain and fatigue in patients with CD and whether changes in abdominal pain and fatigue mediate any beneficial effects of COBMINDEX on impairments in work productivity and daily activities. Methods: This is a secondary analysis of a parallel-group multicentre randomised controlled trial. Patients with mild-to-moderate CD (n = 142) were randomised into either intervention group receiving COBMINDEX, or control group receiving treatment-as-usual for 3 months followed by COBMINDEX. Complete data were collected from 120 patients (34.0 ± 10.7 years, 62.5% female, intervention = 60, control = 60). Analysis of covariance assessed group differences in 3-month follow-up scores, controlling for baseline scores. Multiple parallel mediation analysis assessed the proposed mechanisms for the entire sample. Results: The intervention group demonstrated significantly lower levels of abdominal pain (F = 17.46, p < 0.001, η2p = 0.13), fatigue (F = 7.26, p = 0.008, η2p = 0.06) and impairments at work (F = 4.82, p = 0.032, η2p = 0.07) and daily activities (F = 6.26, p = 0.014, η2p = 0.05), compared with treatment-as-usual. Moreover, changes in abdominal pain and fatigue significantly mediated the beneficial effects of COBMINDEX on patients' work productivity (b = −9.90, SE = 2.86, 95% CI: −16.11 to −4.94) and daily activities (b = −9.65, SE = 1.91, 95% CI: −13.77 to 6.35), independent of changes in disease activity. Conclusions: COBMINDEX is effective at reducing abdominal pain and fatigue in patients with CD, which in turn leads to improvement in functioning. Clinicians should incorporate screening for severe abdominal pain and fatigue and consider offering cognitive-behavioural and mindfulness training. ClinicalTrials.gov, Number: NCT05085925. Ministry of Health in Israel (https://my.health.gov.il/CliniTrials/Pages/MOH_2020-02-24_008721.aspx).
KW - abdominal pain
KW - disability
KW - fatigue
KW - inflammatory bowel disease
KW - mediation analysis
KW - randomised controlled trial
UR - http://www.scopus.com/inward/record.url?scp=85147435163&partnerID=8YFLogxK
U2 - 10.1111/apt.17399
DO - 10.1111/apt.17399
M3 - Article
C2 - 36734040
AN - SCOPUS:85147435163
SN - 0269-2813
VL - 57
SP - 861
EP - 871
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 8
ER -